MiniMed Group, Inc. (MMED) Stock Price & Analysis
MiniMed Group, Inc. (MMED) closed at USD 18 on Thursday, October 15, 2026, up 7.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 16.81; the Oct 15, 2026 session ranged USD 16.6–18.08 on volume of 27,731,697 shares. Market capitalization is $5.06B, with a 52-week range of USD 10.65–24.43 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MMED.md
Key facts (MMED)
- Analysts: Buy (mean 2.31 on a 1–5 scale) (16 analysts), mean target USD 25 (range 15–30).
- Total return with dividends: 1Y -2.6% vs S&P 500 +18.1%; 5Y -2.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD 0.11, revenue estimate $824M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MMED)
| USD | FY2026 | FY2026 | FY2026 | TTM |
|---|---|---|---|---|
| Revenue | $2.47B | $2.71B | $3.10B | — |
| Gross profit | $1.44B | $1.53B | $1.68B | — |
| Operating income | -$69.0M | -$146M | -$190M | — |
| Net income | -$112M | -$213M | -$333M | -$309M |
| EPS (diluted) | -$0.44 | -$0.84 | -$1.30 | — |
| Free cash flow | -$107M | -$53.0M | -$420M | — |
| Gross margin | 58.2% | 56.3% | 54.2% | — |
| Operating margin | -2.8% | -5.4% | -6.1% | — |
| Net margin | -4.5% | -7.8% | -10.7% | — |
| Revenue growth | — | +10.0% | +14.3% | — |
| Cash + short-term investments | $54.0M | $11.0M | $298M | — |
Fiscal years end Apr. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (MMED)
P/B 1.4x · Earnings yield -6.10%
Analysts (MMED)
Consensus Buy (mean 2.31 on a 1–5 scale), 16 analysts; mean target USD 25 (low 15, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | Initiated | Hold | $22 |
| 2026-10-08 | Mizuho | Target raised | Outperform | $26 → $28 |
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $22 |
| 2026-09-24 | Truist Securities | Initiated | Buy | $29 |
| 2026-09-03 | Morgan Stanley | Target raised | Overweight | $19 → $21 |
| 2026-09-02 | Citigroup | Target raised | Buy | $23 → $26 |
| 2026-09-02 | Evercore ISI Group | Target raised | Outperform | $20 → $27 |
| 2026-09-02 | Wells Fargo | Target raised | Overweight | $22 → $26 |
| 2026-09-02 | UBS | Target raised | Buy | $25 → $28 |
| 2026-09-02 | Mizuho | Target raised | Outperform | $21 → $26 |
| 2026-09-02 | B of A Securities | Target raised | Buy | $24 → $28 |
| 2026-09-01 | BTIG | Target raised | Buy | $25 → $28 |
Total return (dividends reinvested) (MMED)
| 1Y (from 2026-03-06) | 5Y (from 2026-03-02) | |
|---|---|---|
| Total return | -2.6% | -2.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 57.6% | 55.0% |
| Max drawdown | -41.6% (Mar 2026→May 2026) | -41.6% (Mar 2026→May 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 18 |
|---|---|
| Change | ▲ 7.08% (up) |
| Previous Close | USD 16.81 |
| Open | USD 16.6 |
| Day Range | USD 16.6 – 18.08 |
| 52-Week Range | USD 10.65 – 24.43 |
| Volume | 27,731,697 shares |
| Market Cap | $5.06B |
| Exchange | NMS |
Technical Analysis (MMED)
Nexqual's technical model rates MMED "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.17 (neutral) |
| vs SMA50 | Below (USD 20.47) |
| MACD | -0.73 (negative) |
Analyst Ratings (MMED)
Wall Street analysts rate MMED "Buy" based on 16 analysts, with a mean price target of USD 25 (range USD 15–30), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 25 |
| High Target | USD 30 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 12 / 3 / 1 |
Earnings (MMED)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD 0.11 |
| Revenue Estimate | $824.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD 0.13 vs est 0.1 ▲ beat |
| 2026-04-30 | USD -0.6 vs est -0.22 ▼ miss |
| 2026-01-31 | USD 0.08 vs est 0.21 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (MMED)
| Total Revenue | $3.22B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +16.60% |
| Gross Margin | +56.89% |
| Operating Margin | +0.47% |
| Profit Margin | -9.74% |
| ROE | -8.66% |
| Debt / Equity | 0.02 |
| Current Ratio | 1.81 |
| Total Cash | $207.00M |
| Total Debt | $59.00M |
| Free Cash Flow (fiscal year ended Apr 2026, SEC 10-K) | -$420.00M (-13.5% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (MMED)
Nexqual rates MiniMed Group, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 57%, operating 0% |
| Balance Sheet | Strong — $207M cash vs $59M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$420M (FY ended Apr 2026, 10-K), burning cash |
| Efficiency | Critical — ROE -9% |
Ownership (MMED)
| Insider Ownership | +89.94% |
|---|---|
| Institutional Ownership | +13.58% |
| Shares Outstanding | 281.35M |
| Float | 28.47M |
| Short % of Float | +63.77% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (MMED)
MiniMed Group, Inc. is led by Que Thanh Dallara (age 51), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | Que Thanh Dallara (age 51) |
|---|---|
| Executive VP & CFO | Chad J. Spooner (age 53) |
| Executive VP and Chief Product & Technology Officer | Ali Dianaty (age 50) |
| President | Christopher E. Eso |
| SVP and Chief Marketing & Communications Officer | Kate Cronin MSN RN (age 59) |
Major Backers & Investors (MMED)
Notable institutional backers of MiniMed Group, Inc. include Massachusetts Financial Services Co., MFS SERIES TRUST XI-MFS Mid Cap Value Fund, Millennium Management, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Massachusetts Financial Services Co. | 2.96% |
| MFS SERIES TRUST XI-MFS Mid Cap Value Fund | 1.78% |
| Millennium Management | 1.09% |
| Citadel | 1.02% |
| Longaeva Partners L.P. | 1% |
| Fidelity | 0.77% |
| Sessa Capital IM, L.P. | 0.71% |
| NORGES BANK | 0.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.97% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STVN | Stevanato Group S.p.A. | USD 19.25 | ▼ 0.05% |
| MMSI | Merit Medical Systems, Inc. | USD 89.57 | ▲ 1.62% |
| TFX | Teleflex Incorporated | USD 128.22 | ▲ 3.04% |
| BLCO | Bausch + Lomb Corporation | USD 16.66 | ▲ 5.38% |
| ICUI | ICU Medical, Inc. | USD 167.23 | ▲ 2.45% |
| NVST | Envista Holdings Corporation | USD 23.5 | ▲ 3.75% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt